Akèy › Limfom selil mantèl › Tennessee › Nashville
Etid klinik pou Limfom selil mantèl nan Nashville, TN
11 etid pou Limfom selil mantèl ap chèche patisipan nan sit nan ak bò kote Nashville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
- Tennessee Oncology, Pllc Nashville, Nashville
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
Ap rekriteFaz 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Ap rekriteFaz 3
- Tennessee Oncology Nashville St Thomas Midtown Clinic, Nashville
- Tennessee Oncology, Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Ap rekriteFaz 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
Ap rekriteFaz 2
- Vanderbilt University/Ingram Cancer Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- TriStar BMT, Nashville
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Tennessee Oncology, Nashville
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- SCRI Oncology Partners, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- Tennessee Oncology, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Nashville
Etid Limfom selil mantèl nan lòt vil
- Houston, TX15 etid
- Baldwin Park, CA15 etid
- Durham, NC13 etid
- New York City, NY12 etid
- Seattle, WA12 etid
- Milwaukee, WI12 etid
- Boston, MA11 etid
- Columbus, OH11 etid
- Chicago, IL10 etid
- Rochester, MN9 etid
- Portland, OR9 etid
- Atlanta, GA8 etid
Lòt etid nan Nashville
- Kansè Poumon ki pa ti selil97 etid
- Kansè nan tete81 etid
- Kansè Metastatik70 etid
- Kansè kolorektal69 etid
- Kansè (tout kalite)65 etid
- Kansè ovè49 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Karsinòm selil skuamèz tèt ak kou39 etid
- Kansè pankreyas39 etid
- Kansè Endomèt38 etid
- Melanom33 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.